中國銀行(601988.SH):擬向全資子公司中銀歐洲增資不超過等值3億歐元
格隆匯6月20日丨中國銀行(601988.SH)公佈,經本行2025年6月20日召開的董事會會議審議通過,本行擬向本行全資子公司中銀歐洲增資,本次增資金額不超過等值3億歐元。本行董事會授權高級管理層在董事會確定的增資額度內決定並辦理本次增資後續具體事宜。
中銀歐洲是本行在盧森堡設立的全資子公司,本次增資前註冊資本為4億歐元。中銀歐洲持有全功能牌照,主要開展存款、貸款、債券投資、匯款等業務。本行增資的資金來源為本行自有資金。本次增資不屬於證券監管規則下的關聯交易或重大資產重組事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.